References
- Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):1–5.
- Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
- Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24(4):455–467.
- Fayard E, Auwerx J, Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and teroidogenesis. Trends Cell Biol. 2004;14(5):250–260.
- Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999;48(12):1589–1595.
- Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001;75(1):46–52.
- Morin-Papunen L, Vauhkonen I, Koivunen R, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85(9):3161–3168.
- da Silva AV, de Melo AS, Barboza RP, et al. Levonorgestrel-Releasing intrauterine system for women with polycystic ovary syndrome: metabolic and clinical effects. Reprod Sci. 2016;23(7):877–884.
- The rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
- Bilian X, Liying Z, Xuling Z, et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception. 1990;41:353–362.
- Park JC, Lim SY, Jang TK, et al. Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clin Exp Reprod Med. 2011;38(1):42–46.
- Lockhat FB, Emembolu JE, Konje JC. Serum and peritoneal fluid levels of evonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil Steril. 2005;83(2):398–404.
- Nilsson CG, Haukkamaa M, Vierola H, et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel⁃releasing IUD[J]. Clin Endocrinol (Oxf). 1982;17(6):529–536.
- Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782–785.
- Lang JH, Leng JH, , Deng S, , et al. Consensus of chinese experts on the clinical application of levonorgestrel intrauterine sustained release system. Chin J Obstet Gynecol. 2019;54:815–825.